| MCUJF Stock | | | USD 0.70 0.00 0.00% |
Chairman
Dr. Albert D. Friesen Ph.D. is Chairman of the Board, Chief Executive Officer of the company. and is no longer as President of the company, Effective July 01, 2019. Dr. Friesen holds a Ph.D. in protein chemistry from the University of Manitoba. Dr. Friesen played a key role in founding several health industry companies including Rh Pharmaceuticals, ABI Biotechnology, Viventia Biotech Inc., Genesys Pharma Inc. and KAM Scientific Inc. Dr. Friesen has experience in the establishment of pharmaceutical production facilities and has also managed and initiated the research and clinical development of several pharmaceutical candidates. Dr. Friesen is a founder of the Industrial Biotechnology Association of Canada and past Chairman of its board of directors and former member of the Industrial Advisory Committee to the Biotechnology Research Institute in Montreal. In addition to his role with the Company, Dr. Friesen is currently the President and Chairman of Genesys Venture Inc., a biotech incubator, based in Winnipeg. Dr. Friesen provides his services to the Company through A.D. Friesen Enterprises Ltd., his private consulting corporation.He also served as President until July 25, 2011 at which point that position was filled by Mr. Dawson Reimer. Date of birth is May 19, 1947 since 2019.
| Age | 76 |
| Tenure | 5 years |
| Phone | 204 487 7412 |
| Web | https://www.medicure.com |
Medicure Management Efficiency
The company has return on total asset
(ROA) of
0.021 % which means that it generated a profit of $0.021 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
0.1483 %, meaning that it generated $0.1483 on every $100 dollars invested by stockholders. Medicure's management efficiency ratios could be used to measure how well Medicure manages its routine affairs as well as how well it operates its assets and liabilities.
Medicure has accumulated 1.02
M in total debt with debt to equity ratio
(D/E) of 0.05, which may suggest the company is not taking enough advantage from borrowing. Medicure has a current ratio of 1.44, which is within standard range for the sector. Debt can assist Medicure until it has trouble settling it off, either with new capital or with free cash flow. So, Medicure's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Medicure sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Medicure to invest in growth at high rates of return. When we think about Medicure's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 1 records | CHAIRMAN Age |
| Peter Luo | Adagene | 58 |
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market in Canada and the United States. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada. Medicure is traded on OTC Exchange in the United States. Medicure [MCUJF] is a
Pink Sheet which is traded between brokers as part of OTC trading.
Management Performance
Medicure Leadership Team
Elected by the shareholders, the Medicure's board of directors comprises two types of representatives: Medicure inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Medicure. The board's role is to monitor Medicure's management team and ensure that shareholders' interests are well served. Medicure's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Medicure's outside directors are responsible for providing unbiased perspectives on the board's policies.
Medicure Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Medicure a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Other Information on Investing in Medicure Pink Sheet
Medicure financial ratios help investors to determine whether Medicure Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medicure with respect to the benefits of owning Medicure security.